Impax Laboratories (NASDAQ: IPXL) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Impax Laboratories and SCYNEXIS’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Impax Laboratories $812.82 million 1.88 $144.42 million ($8.07) -2.63
SCYNEXIS $256,999.00 256.82 -$25.04 million N/A N/A

Impax Laboratories has higher revenue and earnings than SCYNEXIS.

Analyst Recommendations

This is a summary of current recommendations for Impax Laboratories and SCYNEXIS, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impax Laboratories 1 9 5 0 2.27
SCYNEXIS 0 1 5 1 3.00

Impax Laboratories presently has a consensus price target of $19.67, indicating a potential downside of 7.45%. SCYNEXIS has a consensus price target of $10.57, indicating a potential upside of 327.99%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Impax Laboratories.

Profitability

This table compares Impax Laboratories and SCYNEXIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Impax Laboratories -71.08% 9.05% 3.20%
SCYNEXIS -9,648.47% -64.04% -37.19%

Insider and Institutional Ownership

86.3% of Impax Laboratories shares are owned by institutional investors. Comparatively, 36.8% of SCYNEXIS shares are owned by institutional investors. 3.2% of Impax Laboratories shares are owned by company insiders. Comparatively, 4.0% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Impax Laboratories has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

Summary

Impax Laboratories beats SCYNEXIS on 7 of the 12 factors compared between the two stocks.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

SCYNEXIS Company Profile

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.